US Patent

US7915307 — Methods of improving the pharmacokinetics of doxepin

Method of Use · Assigned to Somaxon Pharmaceuticals Inc · Expires 2027-08-24 · 1y remaining

Vulnerability score 80/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods for improving the pharmacokinetics of doxepin in a patient.

USPTO Abstract

Methods of improving the pharmacokinetics of doxepin in a patient.

Drugs covered by this patent

doxepin-hydrochloride (DOXEPIN HYDROCHLORIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-620`	—	doxepin-hydrochloride
`U-620`	—	doxepin-hydrochloride

Patent Metadata

Patent number: US7915307
Jurisdiction: US
Classification: Method of Use
Expires: 2027-08-24
Drug substance claim: No
Drug product claim: No
Assignee: Somaxon Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.